Company intelligence / Profile preview
Therawisdom Biopharma
Shandong Sheng, Chinaglobenewswire.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Therawisdom Biopharma is a private Chinese biotech company founded in 2019, focused on developing biologic therapies—primarily monoclonal antibodies, fusion proteins, and bispecific antibodies—for oncology and reproductive health. Its lead assets are in early clinical development for solid tumors, infertility, and urogenital diseases. The company has at least three programs in Phase 1 trials as of mid‑2025[1][7].
- Therapeutic areas
- NephrologyWomen's HealthOncology
- Modalities
- Monoclonal antibodyFusion proteinBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Therawisdom Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Therawisdom Biopharma.